According to the latest report by IMARC Group, titled “Premenstrual Syndrome Treatment Market: Global Industry Trends, Share, Growth, Opportunity and Forecast 2022-2027,“ The global premenstrual syndrome treatment market size reached US$ 1,287.9 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 1,622.7 Million by 2027, exhibiting a growth rate (CAGR) of 3.99% during 2022-2027.
Premenstrual syndrome (PMS) refers to a set of emotional, physical, and psychological symptoms that occur in women during the end of the luteal phase. It is caused by the elevated levels of progesterone and estrogen. Some of the common PMS symptoms include mood swings, breast tenderness, bloating, fatigue, anxiety, and body pain. PMS treatment involves various medications that help to increase the levels of serotonin hormone in the body. These treatments include analgesics, antidepressants, nonsteroidal anti-inflammatory drugs (NSAIDs), ovarian suppression agents, and hormonal contraceptives.
The increasing prevalence of PMS and premenstrual dysphoric disorder (PMDD) is primarily driving the market growth. The rising awareness regarding the availability of alternative PMS treatment methods is further catalyzing the market growth. In line with this, pharmaceutical companies are investing in research and development (R&D) activities to launch medications with minimal side-effects, which is contributing to the market growth. Additionally, the widespread adoption of plant-based nutritional supplements for PMS relief is presenting numerous growth opportunities to leading players in the market, thus creating a positive outlook for the market.
Request Free Sample Report: https://www.imarcgroup.com/premenstrual-syndrome-treatment-market/requestsample
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
- AbbVie Inc
- BASF SE
- Bayer AG
- Dr. Reddy’s Laboratories Ltd
- Eli Lilly and Company
- GlaxoSmithKline Plc
- H. Lundbeck A/S
- Pfizer Inc
- SHIONOGI Co. Ltd
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/premenstrual-syndrome-treatment-market
The report has segmented the market on the basis on region, drug type, type, distribution channel.
Breakup by Drug Type:
- Oral Contraceptives and Ovarian Suppression Agents
Breakup by Type:
Breakup by Distribution Channel:
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Stores
Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800